Convatec Group (2CV) Stock Overview
Engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
2CV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Convatec Group PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.62 |
| 52 Week High | UK£3.52 |
| 52 Week Low | UK£2.42 |
| Beta | 0.76 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -14.38% |
| 3 Year Change | -2.24% |
| 5 Year Change | 15.32% |
| Change since IPO | 5.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2CV | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -8.4% | -5.1% | -2.4% |
| 1Y | -14.4% | -26.5% | -0.2% |
Return vs Industry: 2CV exceeded the German Medical Equipment industry which returned -26.5% over the past year.
Return vs Market: 2CV underperformed the German Market which returned -0.2% over the past year.
Price Volatility
| 2CV volatility | |
|---|---|
| 2CV Average Weekly Movement | 5.1% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in DE Market | 14.4% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 2CV has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2CV's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,910 | Jonny Mason | www.convatecgroup.com |
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma.
Convatec Group PLC Fundamentals Summary
| 2CV fundamental statistics | |
|---|---|
| Market cap | €5.35b |
| Earnings (TTM) | €151.97m |
| Revenue (TTM) | €2.12b |
Is 2CV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2CV income statement (TTM) | |
|---|---|
| Revenue | US$2.44b |
| Cost of Revenue | US$1.07b |
| Gross Profit | US$1.37b |
| Other Expenses | US$1.20b |
| Earnings | US$175.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.09 |
| Gross Margin | 56.25% |
| Net Profit Margin | 7.18% |
| Debt/Equity Ratio | 92.1% |
How did 2CV perform over the long term?
See historical performance and comparisonDividends
Does 2CV pay a reliable dividends?
See 2CV dividend history and benchmarks| Convatec Group dividend dates | |
|---|---|
| Ex Dividend Date | Apr 16 2026 |
| Dividend Pay Date | May 28 2026 |
| Days until Ex dividend | 34 days |
| Days until Dividend pay date | 76 days |
Does 2CV pay a reliable dividends?
See 2CV dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 00:32 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Convatec Group PLC is covered by 25 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hassan Al-Wakeel | Barclays |
| Samuel England | Berenberg |
| Susannah Ludwig | Bernstein |